Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV terlipressin added to inhaled nitric oxide for persistent pulmonary hypertension of the newborn
ChiCTR2600122623Phase 4Recruiting
- Sponsor
- West China Second University Hospital
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of terlipressin in persistent pulmonary hypertension of the newborn (PPHN) (2 arms), sponsored by West China Second University Hospital. Primary endpoints: Extracorporeal Membrane Oxygenation use and Death (all-cause mortality). Started Apr 2026; status: recruiting.
02
Drugs
terlipressin
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on ChiCTR2600122623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122623.